Compare IAC/Interactivecorp (PPLI) vs Summit Therapeutics Inc (SMMT) Price & Performance

PPLI trades at $38.38, down 1.56% today, with a bearish technical signal from moving averages. The company reported mixed quarterly results, including a significant Q2 2026 earnings beat of $6.77 per share versus expectations of a $0.40 loss, driven by gains from its MGM investment. Revenue has declined from $5.2B in 2022 to $2.4B in 2025, though 2026 projections show improved profitability with a 14.12% net margin. Recent news highlights participation in investor conferences and strategic focus on monetizing non-core assets.

The investment outlook is cautiously optimistic, supported by a 69% analyst buy rating and a $58.80 consensus price target implying 53% upside. Key opportunities include the undervalued MGM stake exceeding market cap and improving digital revenue. Risks involve declining revenue trends, negative operating cash flow in 2026, and a shareholder investigation announced in August 2026. The stock's low P/E of 6.49 and P/B of 0.56 suggest valuation appeal if execution improves.

Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion in 2025, with negative ROE and ROA, while P/B stands at 22.19. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancer, driving investor optimism ahead of a key FDA decision in November 2026.

The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.18 suggesting 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish with 61% buy ratings, but the stock remains speculative due to its pre-revenue status and dependence on a single drug candidate.